After Synergy Pharmaceuticals Inc (NASDAQ:SGYP) yielded positive Phase 3 top-line data in the first of two pivotal Phase 3 trials in adults with …
In a research report published Monday, H.C.
In a research report released Friday, Canaccord analyst John Newman reiterated a Buy rating on shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) with a $13 price …
Here are some of the biggest movers in the market today, for better or for worse: Interpace Diagnostics Group Inc (NASDAQ:IDXG), Synergy Pharmaceuticals …
As Synergy Pharmaceuticals Inc (NASDAQ:SGYP) prepares to release top-line results from two pivotal Phase 3 IBS-C trials before 2016 ends, BTIG analyst Tim …
Analysts are offering their two cents on biotech firms Amicus Therapeutics, Inc. (NASDAQ:FOLD) and Synergy Pharmaceuticals Inc (NASDAQ:SGYP).
Canaccord analyst John Newman was out pounding the table on shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP), reiterating a buy rating and price target of $13, …
As both earnings and election season are coming to a close, analysts are chiming in with varied expectations for three biotech players: Valeant …
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) announced its financial results and business update for the three months ended September 30, 2016. “This was another exciting quarter …
H.C.
